WO2002017957A1 - Preparations de solutions stabilisees sur une longue periode de temps - Google Patents
Preparations de solutions stabilisees sur une longue periode de temps Download PDFInfo
- Publication number
- WO2002017957A1 WO2002017957A1 PCT/JP2001/007600 JP0107600W WO0217957A1 WO 2002017957 A1 WO2002017957 A1 WO 2002017957A1 JP 0107600 W JP0107600 W JP 0107600W WO 0217957 A1 WO0217957 A1 WO 0217957A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- csf
- solution preparation
- preparation according
- csf solution
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/362,921 US7998929B2 (en) | 2000-09-01 | 2001-09-03 | Solution preparations stabilized over long time |
AU8260701A AU8260701A (en) | 2000-09-01 | 2001-09-03 | Solution preparations stabilized over long time |
CA002420850A CA2420850A1 (en) | 2000-09-01 | 2001-09-03 | Solution formulations having long-term stability |
EP01961312A EP1329224A4 (en) | 2000-09-01 | 2001-09-03 | PREPARATIONS OF STABILIZED SOLUTIONS OVER A LONG PERIOD OF TIME |
AU2001282607A AU2001282607B2 (en) | 2000-09-01 | 2001-09-03 | Solution preparations stabilized over long time |
NZ524482A NZ524482A (en) | 2000-09-01 | 2001-09-03 | Solution formulations having long-term stability |
KR10-2003-7002698A KR20030027077A (ko) | 2000-09-01 | 2001-09-03 | 장기 안정화 용액 제제 |
HK04100026A HK1057168A1 (en) | 2000-09-01 | 2004-01-02 | Solution preparations stabilized over long time. |
AU2006235962A AU2006235962A1 (en) | 2000-09-01 | 2006-11-10 | Solution formulations having long-term stability |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000266095 | 2000-09-01 | ||
JP2000-266095 | 2000-09-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002017957A1 true WO2002017957A1 (fr) | 2002-03-07 |
Family
ID=18753248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/007600 WO2002017957A1 (fr) | 2000-09-01 | 2001-09-03 | Preparations de solutions stabilisees sur une longue periode de temps |
Country Status (9)
Country | Link |
---|---|
US (1) | US7998929B2 (ja) |
EP (2) | EP1930024A3 (ja) |
KR (1) | KR20030027077A (ja) |
CN (1) | CN1204921C (ja) |
AU (3) | AU2001282607B2 (ja) |
CA (1) | CA2420850A1 (ja) |
HK (1) | HK1057168A1 (ja) |
NZ (1) | NZ524482A (ja) |
WO (1) | WO2002017957A1 (ja) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004019966A1 (ja) * | 2002-08-27 | 2004-03-11 | Chugai Seiyaku Kabushiki Kaisha | タンパク質溶液製剤の安定化方法 |
WO2004035096A1 (fr) * | 2002-10-15 | 2004-04-29 | Vardosanidze, Irina Viktorovna | Composition possedant des proprietes oxydoreductrices stabilisees et procede de stabilisation de proprietes oxydoreductrices |
JP2006502116A (ja) * | 2002-07-12 | 2006-01-19 | メダレックス, インク. | タンパク質の酸化分解を防ぐ方法及び組成物 |
JP2007502252A (ja) * | 2003-08-14 | 2007-02-08 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 第vii因子ポリペプチドの液状水性医薬組成物 |
JP2007516274A (ja) * | 2003-12-23 | 2007-06-21 | ファルマシア コーポレーション | 安定な成長ホルモン液体製剤 |
US7605124B2 (en) | 2004-09-27 | 2009-10-20 | Canon Kabushiki Kaisha | Ejection liquid and ejection method |
JP2010523510A (ja) * | 2007-04-05 | 2010-07-15 | サンド アクチエンゲゼルシャフト | 安定な水性g‐csf製剤 |
US8617568B2 (en) | 2007-07-10 | 2013-12-31 | Medy-Tox, Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
US8833363B2 (en) | 2004-09-27 | 2014-09-16 | Canon Kabushiki Kaisha | Ejection liquid, ejection method, method for forming liquid droplets, liquid ejection cartridge and ejection apparatus |
US9023992B2 (en) | 2004-05-04 | 2015-05-05 | Novo Nordisk Healthcare Ag | Hydrophobic interaction chromatography purification of factor VII polypeptides |
US9155697B2 (en) | 2006-10-09 | 2015-10-13 | Daewoong Co., Ltd. | Stable liquid compositions for treating stomatitis comprising epidermal growth factor |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
USRE47150E1 (en) | 2010-03-01 | 2018-12-04 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI) |
US11008394B2 (en) | 2007-12-27 | 2021-05-18 | Chugai Seiyaku Kabushiki Kaisha | High concentration antibody-containing liquid formulation |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007034509A2 (en) * | 2005-09-19 | 2007-03-29 | Zenotech Laboratories Limited | Recombinant granulocyte-colony stimulating factor formulation and process |
CA2692165A1 (en) * | 2007-06-25 | 2008-12-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
CN104689333B (zh) * | 2007-08-27 | 2018-05-29 | 拉蒂奥法姆有限责任公司 | G-csf 缀合物的液体制剂 |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
PL3257524T3 (pl) * | 2015-02-11 | 2021-03-08 | Gmax Biopharm Llc | Stabilny preparat farmaceutyczny w postaci roztworu białka fuzyjnego przeciwciała przeciwko glp-1r |
WO2023066988A1 (en) | 2021-10-19 | 2023-04-27 | Sandoz Ag | Glass container with low aluminum content and gas overlay to prevent oxidation of sensitive therapeutic agents |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2193631A (en) * | 1986-07-18 | 1988-02-17 | Chugai Pharmaceutical Co Ltd | Stable granulocyte colony stimulating factor composition |
JPS63146829A (ja) * | 1986-07-18 | 1988-06-18 | Chugai Pharmaceut Co Ltd | 安定な顆粒球コロニ−刺激因子含有製剤 |
WO1992015614A1 (en) * | 1991-03-01 | 1992-09-17 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
US5358708A (en) * | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
US5919757A (en) * | 1992-12-18 | 1999-07-06 | Boehringer Mannheim Gmbh | Aqueous pharmaceutical preparations of G-CSF with a long shelf life |
WO2000051629A1 (fr) * | 1999-03-01 | 2000-09-08 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilisees a longue conservation |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2577742B2 (ja) | 1986-07-18 | 1997-02-05 | 中外製薬株式会社 | 安定な顆粒球コロニ−刺激因子含有製剤 |
JPH02116515A (ja) | 1988-10-26 | 1990-05-01 | Matsushita Electric Works Ltd | 無機質建材の製造方法 |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
DE4126984A1 (de) | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke |
DE4242863A1 (de) | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF |
NZ260909A (en) * | 1993-07-05 | 1995-04-27 | Takeda Chemical Industries Ltd | Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution |
US5607400A (en) * | 1995-05-19 | 1997-03-04 | Becton, Dickinson And Company | Pre-fillable syringe and stopper assembly therefor |
CN1264569C (zh) * | 1998-03-06 | 2006-07-19 | 中外制药株式会社 | 无蛋白制剂 |
US6646110B2 (en) * | 2000-01-10 | 2003-11-11 | Maxygen Holdings Ltd. | G-CSF polypeptides and conjugates |
-
2001
- 2001-09-03 EP EP08004081A patent/EP1930024A3/en not_active Withdrawn
- 2001-09-03 AU AU2001282607A patent/AU2001282607B2/en not_active Ceased
- 2001-09-03 CN CNB018149936A patent/CN1204921C/zh not_active Expired - Fee Related
- 2001-09-03 NZ NZ524482A patent/NZ524482A/en unknown
- 2001-09-03 CA CA002420850A patent/CA2420850A1/en not_active Abandoned
- 2001-09-03 EP EP01961312A patent/EP1329224A4/en not_active Withdrawn
- 2001-09-03 US US10/362,921 patent/US7998929B2/en not_active Expired - Fee Related
- 2001-09-03 AU AU8260701A patent/AU8260701A/xx active Pending
- 2001-09-03 KR KR10-2003-7002698A patent/KR20030027077A/ko not_active Application Discontinuation
- 2001-09-03 WO PCT/JP2001/007600 patent/WO2002017957A1/ja not_active Application Discontinuation
-
2004
- 2004-01-02 HK HK04100026A patent/HK1057168A1/xx not_active IP Right Cessation
-
2006
- 2006-11-10 AU AU2006235962A patent/AU2006235962A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2193631A (en) * | 1986-07-18 | 1988-02-17 | Chugai Pharmaceutical Co Ltd | Stable granulocyte colony stimulating factor composition |
JPS63146829A (ja) * | 1986-07-18 | 1988-06-18 | Chugai Pharmaceut Co Ltd | 安定な顆粒球コロニ−刺激因子含有製剤 |
WO1992015614A1 (en) * | 1991-03-01 | 1992-09-17 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
US5919757A (en) * | 1992-12-18 | 1999-07-06 | Boehringer Mannheim Gmbh | Aqueous pharmaceutical preparations of G-CSF with a long shelf life |
US5358708A (en) * | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
WO2000051629A1 (fr) * | 1999-03-01 | 2000-09-08 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilisees a longue conservation |
Non-Patent Citations (1)
Title |
---|
See also references of EP1329224A4 * |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8029609B2 (en) | 2000-08-07 | 2011-10-04 | Canon Kabushiki Kaisha | Ejection liquid, ejection device, ejection cartridge, and method of making droplets from liquid |
JP2006502116A (ja) * | 2002-07-12 | 2006-01-19 | メダレックス, インク. | タンパク質の酸化分解を防ぐ方法及び組成物 |
JPWO2004019966A1 (ja) * | 2002-08-27 | 2005-12-15 | 中外製薬株式会社 | タンパク質溶液製剤の安定化方法 |
WO2004019966A1 (ja) * | 2002-08-27 | 2004-03-11 | Chugai Seiyaku Kabushiki Kaisha | タンパク質溶液製剤の安定化方法 |
JP4489591B2 (ja) * | 2002-08-27 | 2010-06-23 | 中外製薬株式会社 | タンパク質溶液製剤の安定化方法 |
WO2004035096A1 (fr) * | 2002-10-15 | 2004-04-29 | Vardosanidze, Irina Viktorovna | Composition possedant des proprietes oxydoreductrices stabilisees et procede de stabilisation de proprietes oxydoreductrices |
EA007791B1 (ru) * | 2002-10-15 | 2007-02-27 | Вардосанидзе, Ирина Викторовна | Состав со стабилизированными окислительно-восстановительными свойствами и способ стабилизации окислительно-восстановительных свойств |
JP2007502252A (ja) * | 2003-08-14 | 2007-02-08 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 第vii因子ポリペプチドの液状水性医薬組成物 |
JP2012051893A (ja) * | 2003-08-14 | 2012-03-15 | Novo Nordisk Health Care Ag | 第vii因子ポリペプチドの液状水性医薬組成物 |
JP2007516274A (ja) * | 2003-12-23 | 2007-06-21 | ファルマシア コーポレーション | 安定な成長ホルモン液体製剤 |
JP4845741B2 (ja) * | 2003-12-23 | 2011-12-28 | ファルマシア コーポレーション | 安定な成長ホルモン液体製剤 |
US8338374B2 (en) | 2003-12-23 | 2012-12-25 | Pharmacia Corporation | Stable growth hormone liquid formulation |
US9023992B2 (en) | 2004-05-04 | 2015-05-05 | Novo Nordisk Healthcare Ag | Hydrophobic interaction chromatography purification of factor VII polypeptides |
US10844110B2 (en) | 2004-05-04 | 2020-11-24 | Novo Nordisk Healthcare Ag | O-linked glycoforms of polypeptides and method to manufacture them |
US7605124B2 (en) | 2004-09-27 | 2009-10-20 | Canon Kabushiki Kaisha | Ejection liquid and ejection method |
US8833363B2 (en) | 2004-09-27 | 2014-09-16 | Canon Kabushiki Kaisha | Ejection liquid, ejection method, method for forming liquid droplets, liquid ejection cartridge and ejection apparatus |
US7827982B2 (en) | 2004-09-27 | 2010-11-09 | Canon Kabushiki Kaisha | Ejection liquid and ejection method |
US9155697B2 (en) | 2006-10-09 | 2015-10-13 | Daewoong Co., Ltd. | Stable liquid compositions for treating stomatitis comprising epidermal growth factor |
JP2010523510A (ja) * | 2007-04-05 | 2010-07-15 | サンド アクチエンゲゼルシャフト | 安定な水性g‐csf製剤 |
US9220780B2 (en) | 2007-07-10 | 2015-12-29 | Medy-Tox Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
US10293034B2 (en) | 2007-07-10 | 2019-05-21 | Medy-Tox, Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability and method of use |
US8617568B2 (en) | 2007-07-10 | 2013-12-31 | Medy-Tox, Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
US11008394B2 (en) | 2007-12-27 | 2021-05-18 | Chugai Seiyaku Kabushiki Kaisha | High concentration antibody-containing liquid formulation |
US11359026B2 (en) | 2007-12-27 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | High concentration antibody-containing liquid formulation |
US11584798B2 (en) | 2007-12-27 | 2023-02-21 | Hoffmann-La Roche Inc. | High concentration antibody-containing liquid formulation |
US11767363B2 (en) | 2007-12-27 | 2023-09-26 | Chugai Seiyaku Kabushiki Kaisha | High concentration antibody-containing liquid formulation |
USRE47150E1 (en) | 2010-03-01 | 2018-12-04 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI) |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US9849181B2 (en) | 2012-08-31 | 2017-12-26 | Bayer Healthcare Llc | High concentration antibody and protein formulations |
Also Published As
Publication number | Publication date |
---|---|
EP1930024A3 (en) | 2008-08-06 |
EP1329224A4 (en) | 2004-04-14 |
AU2006235962A1 (en) | 2006-11-30 |
AU8260701A (en) | 2002-03-13 |
HK1057168A1 (en) | 2004-03-19 |
US7998929B2 (en) | 2011-08-16 |
CA2420850A1 (en) | 2003-02-28 |
EP1930024A2 (en) | 2008-06-11 |
AU2001282607B2 (en) | 2006-08-17 |
CN1449292A (zh) | 2003-10-15 |
KR20030027077A (ko) | 2003-04-03 |
CN1204921C (zh) | 2005-06-08 |
US20040037803A1 (en) | 2004-02-26 |
EP1329224A1 (en) | 2003-07-23 |
NZ524482A (en) | 2005-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002017957A1 (fr) | Preparations de solutions stabilisees sur une longue periode de temps | |
JP4607336B2 (ja) | 長期安定化製剤 | |
JP6076226B2 (ja) | タンパク質溶液製剤およびその安定化方法 | |
JP4683810B2 (ja) | 長期安定化製剤 | |
KR930004597B1 (ko) | 과립구 콜로니 자극인자를 함유하는 안정한 약제 및 그의 제조방법 | |
JP3068033B2 (ja) | エリスロポエチン溶液製剤 | |
KR100389726B1 (ko) | 안정한 과립구 콜로니-자극 인자 함유 제제 | |
JP2007204498A (ja) | 長期安定化製剤 | |
EA010979B1 (ru) | Стабилизированные жидкие препаративные формы интерферона | |
JP2577742B2 (ja) | 安定な顆粒球コロニ−刺激因子含有製剤 | |
JP2006116345A (ja) | タンパク質溶液製剤およびその安定化方法 | |
JP4454571B2 (ja) | 蛋白非添加製剤 | |
JP2629000B2 (ja) | 安定な顆粒球コロニー刺激因子含有製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020037002698 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002522930 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001282607 Country of ref document: AU Ref document number: 10362921 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 524482 Country of ref document: NZ Ref document number: 2420850 Country of ref document: CA Ref document number: 018149936 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001961312 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037002698 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001961312 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 524482 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 524482 Country of ref document: NZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001961312 Country of ref document: EP |